Taysha Gene Therapies Net Worth 2020-2025 | TSHA

Interactive chart of historical net worth (market cap) for Taysha Gene Therapies (TSHA) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Taysha Gene Therapies net worth as of June 19, 2025 is $0.55B.
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.552B $0.008B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.567B 6.99
Dr Reddy's Laboratories (RDY) India $12.680B 23.01
BridgeBio Pharma (BBIO) United States $7.595B 0.00
Bausch Health Cos (BHC) Canada $2.287B 1.65
Supernus Pharmaceuticals (SUPN) United States $1.845B 14.98
Amphastar Pharmaceuticals (AMPH) United States $1.195B 8.02
Personalis (PSNL) United States $0.577B 0.00
Assembly Biosciences (ASMB) United States $0.131B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00